COHANCE · NSE
Not in active coverage. Cited reporting has mentioned Cohance Lifesciences, the record of those mentions is below. Your interest is logged; coverage expands by demand.
Cohance Lifesciences' API manufacturing facility in Jaggaiahpet, Andhra Pradesh, received a Form 483 with five observations from the US Food and Drug Administration (FDA).
Cohance Lifesciences' Telangana units received a Form FDA 483 with four observations from the US FDA following an inspection.
Cohance Lifesciences announced that the United States Food and Drug Administration (USFDA) inspected the Company's formulation plant located at Shamshabad, Telangana, from 27 August to 4 September 2026.
The United States Food and Drug Administration (US FDA) issued a Form FDA 483 with four observations to Cohance Lifesciences' formulation plant in Telangana.
Cohance Lifesciences announced two proposed transactions to strengthen its Antibody-drug Conjugate (ADC) strategy: an additional investment of USD 13 million in NJ Bio and a controlling investment of USD 5 million in Aruka Bio.
Cohance Lifesciences plans to invest a combined $18 million in NJ Bio and Aruka Bio to deepen its push into antibody-drug conjugates.
Cohance Lifesciences will invest $18 million in NJ Bio and Aruka Bio to strengthen its antibody-drug conjugate strategy, increasing its NJ Bio ownership to 67.3% and taking a 65% stake in Aruka Bio.
Piramal Pharma, Anthem Biosciences, and Cohance Lifesciences are listed Indian CDMO companies with disclosed ADC-related capabilities, programmes, and investments.
Cohance Lifesciences Group CEO Umang Vohra stated that the company expects improvement in Q2 and a return to year-on-year growth from the second half.
Umang Vohra, former Cipla chief, was appointed by Advent International as executive chairman and Group CEO of Cohance Lifesciences in April 2026, succeeding Vivek Sharma.
This page lists where cited reporting has mentioned Cohance Lifesciences. It is not the full dossier: developments here are single mentions, not corroborated records. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.